Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H16ClN3O3S |
| Molecular Weight | 365.835 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1N(CC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C(=C3)S(N)(=O)=O
InChI
InChIKey=BHUKYXOYJMLRAK-UHFFFAOYSA-N
InChI=1S/C16H16ClN3O3S/c1-10-13-5-3-2-4-12(13)9-20(10)19-16(21)11-6-7-14(17)15(8-11)24(18,22)23/h2-8,10H,9H2,1H3,(H,19,21)(H2,18,22,23)
| Molecular Formula | C16H16ClN3O3S |
| Molecular Weight | 365.835 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.google.com/patents/US4338331
In rodents zidapamide can be administered orally in a dose of 2.5-5 mg per day, depending upon whether it is required to utilize its hypertensive or diuretic action.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:30:23 GMT 2025
by
admin
on
Wed Apr 02 09:30:23 GMT 2025
|
| Record UNII |
F7KU1MIY58
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C448
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5129
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
3033626
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL6378
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
C82267
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
U-32
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
F7KU1MIY58
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
100000079415
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
SUB00151MIG
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
278-321-2
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
75820-08-5
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY | |||
|
DTXSID6048834
Created by
admin on Wed Apr 02 09:30:23 GMT 2025 , Edited by admin on Wed Apr 02 09:30:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |